Search Results

Y-27632 1mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Y-27632 5mg  | ≥98%

CSNpharm

Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.

More Information Supplier Page

Zanamivir 5mg  | ≥99%

CSNpharm

Zanamivir is the first of two registered neuraminidase inhibitors for the treatment and prophylaxis of influenza. Zanamivir could inhibit SARS-CoV-2 3CLpro main protease.

More Information Supplier Page

Zanamivir 10mg  | ≥99%

CSNpharm

Zanamivir is the first of two registered neuraminidase inhibitors for the treatment and prophylaxis of influenza. Zanamivir could inhibit SARS-CoV-2 3CLpro main protease.

More Information Supplier Page

Zanamivir 50mg  | ≥99%

CSNpharm

Zanamivir is the first of two registered neuraminidase inhibitors for the treatment and prophylaxis of influenza. Zanamivir could inhibit SARS-CoV-2 3CLpro main protease.

More Information Supplier Page

Zanamivir 100mg  | ≥99%

CSNpharm

Zanamivir is the first of two registered neuraminidase inhibitors for the treatment and prophylaxis of influenza. Zanamivir could inhibit SARS-CoV-2 3CLpro main protease.

More Information Supplier Page

YC-1 100mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page

YC-1 50mg  | ≥99%

CSNpharm

Lificiguat is an acivator of guanylyl cyclase (sGC) and can bind to the heme-containing domain of the β subunit with Kd of 0.6 μM – 1.1 μM.

More Information Supplier Page